Management expects improved cost efficiency and gross margin in the second half of 2025 from the integration of Elevated Softgels and increased in-source manufacturing. Dowling said, "We expect to see ...
Revenue (GAAP) declined 10.0% year over year to $3.6 million in the first quarter, mainly due to lower unit sales. Gross margin remained steady at 46.0%, with improvements planned for later in 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results